| Ident. | Authors (with country if any) | Title |
|---|
| 000541 |
Hywel D. Williams [Australie] ; Philip Sassene [Danemark] ; Karen Kleberg [Danemark] ; Marilyn Calderone [France] ; Annabel Igonin [France] ; Eduardo Jule [États-Unis] ; Jan Vertommen [France] ; Ross Blundell [France] ; Hassan Benameur [France] ; Anette Müllertz [Danemark] ; Colin W. Pouton [Australie] ; Christopher J. H. Porter [Australie] | Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 3: Understanding Supersaturation Versus Precipitation Potential During the In Vitro Digestion of Type I, II, IIIA, IIIB and IV Lipid-Based Formulations |
| 000B53 |
C. Faivre [France] ; D. Barbolosi [France] ; E. Pasquier [Australie, France] ; N. Andre [France] | A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens |
| 000C39 |
Hywel D. Williams [Australie] ; Philip Sassene [Danemark] ; Karen Kleberg [Danemark] ; Jean-Claude Bakala-N'Goma [France] ; Marilyn Calderone [France] ; Vincent Jannin [France] ; Annabel Igonin [France] ; Anette Partheil [Allemagne] ; Delphine Marchaud [France] ; Eduardo Jule [France] ; Jan Vertommen [France] ; Mario Maio [Allemagne] ; Ross Blundell [France] ; Hassan Benameur [France] ; Frédéric Carriere [France] ; Anette Müllertz [Danemark] ; Christopher J. H. Porter [Australie] ; Colin W. Pouton [Australie] | Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 1: Method Parameterization and Comparison of In Vitro Digestion Profiles Across a Range of Representative Formulations |
| 000E54 |
François Guilhot [France] ; Timothy P. Hughes [Australie] ; Jorge Cortes [États-Unis] ; Brian J. Druker [États-Unis] ; Michele Baccarani [Italie] ; Insa Gathmann [Suisse] ; Michael Hayes [États-Unis] ; Camille Granvil [États-Unis] ; YANFENG WANG [États-Unis] | Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial |
| 001003 |
Nicolas Arlicot [France] ; Johnny Vercouillie [France] ; Maria-João Ribeiro [France] ; Clovis Tauber [France] ; Yann Venel [France] ; Jean-Louis Baulieu [France] ; Serge Maia [France] ; Philippe Corcia [France] ; Michael G. Stabin [États-Unis] ; Aaron Reynolds [Australie] ; Michael Kassiou [Australie] ; Denis Guilloteau [France] | Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation |
| 001068 |
Didier Lebrec [France] ; Jaime Bosch [Espagne] ; Rajiv Jalan [Royaume-Uni] ; Francis J. Dudley [Australie] ; Rada Jessic [Serbie] ; Richard Moreau [France] ; Juan Carlos Garcia-Pagan [Espagne] ; Rajeshwar P. Mookerjee [Royaume-Uni] ; Eleonora Chiossi [Suisse] ; Paul L. M. Van Giersbergen [Suisse] ; Andjela Kusic-Pajic [Suisse] ; Jasper Dingemanse [Suisse] | Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis |
| 001634 |
Annelaure Damont [France] ; Raphael Boisgard [France] ; Bertrand Kuhnast [France] ; Frederic Lemee [France] ; Guillaume Raggiri [France] ; Alana M. Scarf [Australie] ; Eleonora Da Pozzo [Italie] ; Silvia Selleri [Italie] ; Claudia Martini [Italie] ; Bertrand Tavitian [France] ; Michael Kassiou [Australie] ; Frederic Dolle [France] | Synthesis of 6-[18F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET |
| 001800 |
Luis G. Paz-Ares [Espagne] ; Carlos Gomez-Roca [France] ; Jean-Pierre Delord [France] ; Andres Cervantes [Espagne] ; Ben Markman [Espagne, Australie] ; Jesus Corral [Espagne] ; Jean-Charles Soria [France] ; Yann Berge [France] ; Desamparados Roda [Espagne] ; Fiona Russell-Yarde [Royaume-Uni] ; Simon Hollingsworth [Royaume-Uni] ; José Baselga [Espagne] ; Pablo Umana [Suisse] ; Luigi Manenti [Suisse] ; Josep Tabernero [Espagne] | Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors |
| 002156 |
Colin J. Jackson [France] ; Colin Scott [Australie] ; Angela Carville [États-Unis] ; Keith Mansfield [États-Unis] ; David L. Ollis [Australie] ; Steven B. Bird [États-Unis] | Pharmacokinetics of OpdA, an organophosphorus hydrolase, in the African green monkey |
| 003254 |
Jean F. Cuine [Australie] ; Claire L. Mcevoy [Australie] ; William N. Charman [Australie] ; Colin W. Pouton [Australie] ; Glenn A. Edwards [Australie] ; Hassan Benameur [France] ; Christopher J. H. Porter [Australie] | Evaluation of the Impact of Surfactant Digestion on the Bioavailability of Danazol after Oral Administration of Lipidic Self-Emulsifying Formulations to Dogs |
| 003291 |
Laurent Besret [France] ; Frédéric Dolle [France] ; Anne-Sophie Herard [France] ; Martine Guillermier [France] ; Stéphane Demphel [France] ; Francoise Hinnen [France] ; Christine Coulon [France] ; Michèle Ottaviani [France] ; Michel Bottlaender [France] ; Philippe Hantraye [France] ; Michael Kassiou [Australie] | Dopamine D1 Receptor Imaging in the Rodent and Primate Brain Using the Isoquinoline (+)-[11C]A-69024 and Positron Emission Tomography |
| 003532 |
S. Modok [Royaume-Uni] ; R. Scott [Royaume-Uni] ; R. A. Alderden [Australie] ; M. D. Hall [Australie] ; H. R. Mellor [Royaume-Uni] ; S. Bohic [France] ; T. Roose [Royaume-Uni] ; T. W. Hambley [Australie] ; R. Callaghan [Royaume-Uni] | Transport kinetics of four-and six-coordinate platinum compounds in the multicell layer tumour model |
| 004174 |
Michael Williams [Australie] ; Carine L. A. Saison [France] ; Desmond B. Williams [Australie] ; Rai S. Kookana [Australie] | Can aquatic distribution of human pharmaceuticals be related to pharmacological data? |
| 004356 |
Michelle L. James [Australie] ; Roger R. Fulton [Australie] ; David J. Henderson [Australie] ; Stefan Eberl [Australie] ; Steven R. Meikle [Australie] ; Sally Thomson [Australie] ; Robin D. Allan [Australie] ; Frederic Dolle [France] ; Michael J. Fulham [Australie] ; Michael Kassiou [Australie] | Synthesis and in vivo evaluation of a novel peripheral benzodiazepine receptor PET radioligand |
| 004970 |
G. Roger [France] ; F. Dolle [France] ; B. De Bruin [France] ; X. Liu [Australie] ; L. Besret [France] ; Y. Bramoulle [France] ; C. Coulon [France] ; M. Ottaviani [France] ; M. Bottlaender [France] ; H. Valette [France] ; M. Kassiou [Australie] | Radiosynthesis and pharmacological evaluation of [11C]EMD-95885: a high affinity ligand for NR2B-containing NMDA receptors |
| 004971 |
Frédéric Dolle [France] ; Héric Valette [France] ; Stéphane Demphel [France] ; Christine Coulon [France] ; Michelle Ottaviani [France] ; Michel Bottlaender [France] ; Michael Kassiou [Australie] | Radiosynthesis and in vivo evaluation of [11C]Ro-647312: a novel NR1/2B subtype selective NMDA receptor radioligand |
| 004D88 |
Gaëlle Roger [France] ; Béatrice Lagnel [France] ; Laurent Besret [France] ; Yann Bramoulle [France] ; Christine Coulon [France] ; Michelle Ottaviani [France] ; Michael Kassiou [Australie] ; Michel Bottlaender [France] ; Heric Valette [France] ; Frédéric Dolle [France] | Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[11C]one, as a potent NR1A/2B subtype selective NMDA PET radiotracer |
| 005292 |
R. J. Motzer [États-Unis] ; A. Rakhit [États-Unis] ; J. Thompson [États-Unis] ; H. Gurney [Australie, Royaume-Uni] ; P. Selby [Australie, Royaume-Uni] ; R. Figlin [États-Unis] ; S. Negrier [France] ; S. Ernst [Canada] ; M. Siebels [Allemagne] ; M. Ginsberg [États-Unis] ; K. Rittweger [États-Unis] ; L. Hooftman [États-Unis] | Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma |
| 005294 |
J. Baselga [Espagne, Australie, États-Unis, Royaume-Uni, France, Pays-Bas, Italie, Suède] ; D. Rischin ; M. Ranson ; H. Calvert ; E. Raymond ; D. G. Kieback ; S. B. Kaye ; L. Gianni ; A. Harris ; T. Bjork ; S. D. Averbuch ; A. Feyereislova ; H. Swaisland ; F. Rojo ; J. Albanell | Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types |
| 005365 |
D. R. Richardson [Australie] | Iron chelators as therapeutic agents for the treatment of cancer |
| 005572 |
Michael Kassiou [France] ; Christian Loc'H [France] ; Michel Bottlaender [France] ; Karine Mardon [Australie] ; Michele Ottaviani [France] ; Christine Coulon [France] ; Andrew Katsifis [Australie] ; Bernard Maziere [France] | (+)-[76Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET |
| 005D48 |
H. M. Dodds [Australie] ; S. J. Clarke [Australie] ; M. Findlay [Nouvelle-Zélande] ; J. F. Bishop [Australie] ; J. Robert [France] ; L. P. Rivory [Australie] | Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance |
| 005D95 |
V. Carreno [Espagne] ; S. Zeuzem [Allemagne] ; U. Hopf [Allemagne] ; P. Marcellin [France] ; W. G. E. Cooksley [Australie] ; J. Fevery [Belgique] ; M. Diago [Espagne] ; R. Reddy [États-Unis] ; M. Peters [États-Unis] ; K. Rittweger [États-Unis] ; A. Rakhit [États-Unis] ; M. Pardo [Espagne] | A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B |
| 006305 |
P. L. Gambus [Espagne, Allemagne, Australie, États-Unis, France] ; T. W. Schnider ; C. F. Minto ; E. J. Youngs ; V. Billard ; W. G. Brose ; G. Hochhaus ; S. L. Shafer | Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers |
| 006343 |
M.-C. Haaz [France] ; L. Rivory [Australie] ; C. Riche [France] ; L. Vernillet [France] ; J. Robert [France] | Metabolism of irinotecan (CPT-11) by human hepatic microsomes : Participation of cytochrome P-450 3A and drug interactions |
| 006657 |
M. J. Millward [Australie, Allemagne, France] ; J. Zalcberg ; J. F. Bishop ; L. K. Webster ; A. Zimet ; D. Rischin ; G. C. Toner ; J. Laird ; W. Cosolo ; M. Urch ; R. Bruno ; C. Loret ; R. James ; C. Blanc | Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer |
| 006658 |
L. P. Rivory [Australie] ; M.-C. Haaz [France] ; P. Canal [France] ; F. Lokiec [France] ; J.-P. Armand [France] ; J. Robert [France] | Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials |
| 006665 |
P. Baille [France] ; R. Bruno [France] ; J. H. M. Schellens [Pays-Bas] ; L. K. Webster [Australie] ; M. Millward [Australie] ; J. Verweij [Pays-Bas] ; G. Montay [France] | Optimal sampling strategies for bayesian estimation of docetaxel (taxotere) clearance |
| 006709 |
C. F. Minto [États-Unis, Australie, France] ; T. W. Schnider ; T. D. Egan ; E. Youngs ; H. J. M. Lemmens ; P. L. Gambus ; V. Billard ; J. F. Hoke ; K. H. P. Moore ; D. J. Hermann ; K. T. Muir ; J. W. Mandema ; S. L. Shafer | Influence of age and gender on the phamacokinetics and pharmacodynamics of remifentanil. I. Model development |
